These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1974 related articles for article (PubMed ID: 15781101)

  • 1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V; Darnige L; Gaussem P
    Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
    Langabeer SE; Ni Ainle F; Conneally E; Lawler M
    Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
    James C; Ugo V; Le Couédic JP; Staerk J; Delhommeau F; Lacout C; Garçon L; Raslova H; Berger R; Bennaceur-Griscelli A; Villeval JL; Constantinescu SN; Casadevall N; Vainchenker W
    Nature; 2005 Apr; 434(7037):1144-8. PubMed ID: 15793561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
    Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
    Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
    Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
    Campbell PJ; Scott LM; Buck G; Wheatley K; East CL; Marsden JT; Duffy A; Boyd EM; Bench AJ; Scott MA; Vassiliou GS; Milligan DW; Smith SR; Erber WN; Bareford D; Wilkins BS; Reilly JT; Harrison CN; Green AR; ; ;
    Lancet; 2005 Dec; 366(9501):1945-53. PubMed ID: 16325696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.